Core Viewpoint - 石四药集团 has received production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1: Company Developments - 石四药集团's stock rose nearly 3%, currently up 2.68% at HKD 3.06, with a trading volume of HKD 16.01 million [1] - The Indobufene Tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also be used to prevent thrombosis during hemodialysis [1] Group 2: Market Insights - Indobufene Tablets, developed by an Italian company, have become a substitute for aspirin for patients who are intolerant to it [1] - According to the MoShang Pharmaceutical Database, the total hospital sales of Indobufene Tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to exceed 1.9 billion in 2024, with a year-on-year increase of 37.47%, and over 1.1 billion in the first half of 2025, with a year-on-year increase of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]
石四药集团涨近3% 取得吲哚布芬片药品生产注册批件 心血管药物市销逐年增长